

sunstone

THERAPIES

June 27, 2024

Investor Overview

Whole Person Healing, For All

Sunstone Therapies is the leader in the delivery of psychedelic-assisted therapy in the medical setting.

We believe that health is not just the absence of illness, but a state of body, emotional, and social well-being.



Moving Beyond the Traditional

Traditional Oncology

Surgery
Radiation
Chemotherapy

Integrative Oncology

Complete Oncology Care

Psycho-oncology
Palliative Care
Spiritual Support

Sunstone has treated more patients with psychedelic-assisted therapy (PAT) using non-ketamine psychedelics (Psilocybin, MDMA, LSD, 5-MeO-DMT) in the last twelve months than any other organization in the world.



IIDA
HEALTHCARE
DESIGN AWARDS 2022
WINNER

The first purpose built space dedicated to psychedelic treatment within a cancer center



As a physician-led practice, our approach is grounded in rigorous medical standards and a deep respect for the patient experience



Manish Agrawal, MD

CHIEF EXECUTIVE OFFICER

NCI trained medical oncologist with 20+ years of clinical experience and >50K patient encounters. Faculty at the NCI leading drug development in GU cancers. Previously Co-Director of Clinical Research and cancer center director at the Aquilino Cancer Center.



Kim Roddy, MBA

CHIEF OPERATIONS OFFICER

25 years clinical operational experience. Managed > \$1 billion oncology business across eleven locations with 350 employees.




Michael Pollack, MS

DIR OF BUSINESS DEVELOPMENT

Over 20 years of experience on Wall Street, Chief Investment Officer of Destrier Capital Management, general partner at Glenhill Capital Management, and Clinical Professor of Business and Society at NYU Stern.

Our Oncology background gives us the operational know-how to deliver complex care at scale



Industry Leading Care

Sunstone stands at the forefront of PTSD treatment for active-duty military and veterans, showcasing unmatched expertise in this realm.

To date, Sunstone has treated the largest number of patients receiving MDMA-assisted therapy for PTSD in Lykos' Expanded Access Program*.

**Sunstone did not contribute to Lykos' phase 2 or phase 3 data for FDA submission. Expanded Access followed phase 3 studies.*



Industry Leadership: Wide Breadth of Clinical Trials

6

Psychedelic Medicines

- MDMA
- Psilocybin
- 5-MeO-DMT
- LSD
- Methylone
- RE104

9

Treatment Indications


- PTSD Post-Traumatic Stress Disorder
- MDD Major Depressive Disorder
- TRD Treatment-Resistant Depression
- AD Adjustment Disorder
- GAD Generalized Anxiety Disorder
- Cancer & MDD
- Cancer & AD
- End of Life
- Postpartum Depression

11

Open Trials
in 2024*

*13 trials anticipated open in 2025

Key Commercial Partnerships



MindMed



We continue to expand and deepen our partnerships with pharmaceutical partners

Sunstone is pioneering research in PAT

JAMA Oncology

NIH-HEALS


 National Institutes of Health
HEAL Initiative

ACCEPT Study

 Dana-Farber
Cancer Institute

GIPSE Global Initiative for
Psychedelic Science
Economics


VERMONT
CONVERSATION
LAB


Cancer

1. [Agrawal M, et al. Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder. April 2023.](#)
2. [Shnayder S, ...Agrawal M. Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients. Dec 2022.](#)
3. [Beaussant Y .Agrawal M. Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD. Dec 2023.](#)
4. [Marseille E., Stauffer C., Agrawal M., et al. Group psychedelic therapy: empirical estimates of cost-savings and improved access. Dec. 2023.](#)
5. [Gramling R, Agrawal M. Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study. Aug. 2023.](#)
6. [Agrawal M, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with MDD. Dec. 2024.](#)

Delivery Challenges – Sunstone’s Solution

Psychedelic medicines
do not heal on their own



**Treatments are administered by skilled,
experienced mental health professionals**

Trauma can
emerge at anytime



**Training programs are robust to involve
trauma-informed care**

Mental health is isolating



**Group therapy protocols enhance the
treatment**

Screening isn’t
thorough enough




**Rigorous screening protocols ensure patient
eligibility, safety, and suitability**

Patients are released too
soon after treatment



**Tailored support groups for patients following
treatment completion**

Sunstone has a **two-stage operating model** that is ready to transition




Sunstone: Clinical Research Organization Revenue Model: Pharma/Grants (IIT)

- **East Coast Center of Excellence** focused on trial execution and patient experience in treating complex mental health conditions
- On-the-ground **training location for clinical trial therapists**
- A **data platform** to collect, anonymize and share research and patient experience data

Sunstone: Healthcare Delivery Company Revenue Model: Fee for Service, Pharma

- Creator of payor models and standards of care
- **Building and operating Sunstone owned treatment centers in major US cities**
- Creating strategic partnerships that leverage our robust **research and patient experience** platform for data, insights, and therapeutic support
- Platform supporting ongoing **therapist training, qualifications and certification**

Potential Footprint





Thank You



Appendix

Academic Partnerships



Post-doctoral candidate to work at Sunstone exploring various questions including the potential use of functional neuroimaging in clinical studies.



**Memorial Sloan Kettering
Cancer Center**

Investigating the use of Meaning Centered Psychotherapy in Preparation and integration.



Dana-Farber
Cancer Institute

Collaboration on clinical study development and publications. McGill University – Collaboration on clinical trial development



The University of Vermont

Exploring the use of Natural Language Processing on audio/video recordings to measure therapeutic alliance.

Our Therapy Team



Robert Koffman,
MD, MPH
CORE THERAPIST & MILITARY LIAISON



Betsy Jenkins,
LCPC
CORE THERAPIST



Jessica Jones
LCSW-C
CORE THERAPIST



Mark Bates,
PhD
CORE THERAPIST



Norma Stevens,
MS, MCC, LCPC
LEAD OF THERAPY OPERATIONS



Shelby Muhammedi,
LCSW
THERAPY FELLOW



Rachel Winzer,
MS
THERAPIST PROGRAM DIRECTOR



Bill Richards,
PhD
SENIOR ADVISOR

Our Research Team



Amy Zuchelkowski, PhD
RESEARCH DIRECTOR



Celia Leeks
RESEARCH MANAGER



Ben Bregman, MD
PSYCHIATRIST



Gregory Barber, MD
PSYCHIATRIST



Renuka Surujnarain
**CLINICAL RESEARCH COORDINATOR
(CRC)**



Alexandra Tribo
CRC



Jamie Nathlar
CRC



Payal Patel, MD
**CLINICAL EVALUATION SPECIALIST
(CES)**



Tary Hanna, MD
CES



Willie Harrington, MD, MS
CES



Joel Vincent
REGULATORY AFFAIRS



Chris Kritzman
REGULATORY AFFAIRS



Jehenifer Fuentes
MEDICAL ASSISTANT

Operational Team



Durga Bagve
PRACTICE DIRECTOR



Madison Mount
PRODUCT DIRECTOR



Laura Volovski
MARKETING



Lindsay Ozyck
CHIEF OF STAFF



Maricel Claro
ACCOUNTANT



Eakta Agrawal
HEALTHCLOUD LEAD



Michelle Childers
HUMAN RESOURCES



Mehwish Sajjad
SCHEDULING ANALYST



Sahar Din
BOOKKEEPER



Eloise Cherian
COMMUNICATIONS



Chris Smith
TECHNOLOGY



Mike Huneke
DIGITAL ENGINEER



Derek Burks
RECRUITER



Christina Kappil
BUSINESS FELLOW



Chris Pereira
TRAINING

